



ASX Announcement | September 10 2020
Althea Group Holdings (ASX:AGH)

Investor Webinar - CBD products to become available over the counter under proposed TGA reclassification

10 September 2020: Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company') is pleased to invite shareholders and investors to a briefing with CEO Joshua Fegan to discuss the interim decision to down schedule cannabidiol (CBD) released yesterday.

Details of the event are as follows:

Event: Althea Group Holdings Investor Briefing

Presenters: CEO, Joshua Fegan

Time: Friday 11th September 2020, 10.30am (AEST)

Where: Zoom Webinar, details to be provided upon registration

To register your interest for the webinar, please click through to the link below:

https://us02web.zoom.us/webinar/register/WN_R12m0xdvRWSk_XbyHEWDKw

Participants will be able to submit questions via the chat function throughout the webinar, however, to ensure all questions can be answered in the allotted time we encourage shareholders to send through questions via email beforehand to the Company via Investor Relations partner Jane Morgan at jm@janemorganmanagement.com.au

Discussion points:

- The interim decision by the Therapeutic Goods Administration (TGA) to amend the current Poisons Standard to down schedule cannabidiol (CBD) to allow greater access through a new Schedule 3 entry¹
- The result of the proposed amendment which would allow Australian patients to purchase CBD products upon consultation with a pharmacist, without the need for a prescription

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director

M: 1300 70 20 20

E: contact@althea.life

Media Enquiries

Dan Francome

Media Relations

P: +613 9650 5096

E: dfrancome@althea.life

¹ <https://www.tga.gov.au/sites/default/files/notice-interim-decisions-proposed-amendments-poisons-standard-acms-and-joint-acms-accs-meetings-june-2020.pdf>

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.life

P. 1300 70 20 20

W. althea.life



Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global pharmaceutical company and supplier of medicinal cannabis. Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia, United Kingdom and Germany, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.life

P. 1300 70 20 20

W. althea.life